Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Takeda Steps Up Antibody Focus With U.S. Collaborator

This article was originally published in PharmAsia News

Executive Summary

Takeda Pharmaceutical, through its San Francisco subsidiary, has decided to increase its U.S. focus on developing therapeutic antibodies with U.S.-based Xoma. The plan includes increasing collaboration among all of its laboratories, both domestic and foreign. Takeda San Francisco intends to concentrate its efforts in the antibody field, taking advantage of a recent agreement to Xoma to use its advanced technologies and data-management systems. The pact calls for Takeda to choose compounds to study and Xoma to create antibodies for them. (Click here for more - a subscription may be required

Latest Headlines
See All
UsernamePublicRestriction

Register

SC070833

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel